JP2024533093A5 - - Google Patents
Info
- Publication number
- JP2024533093A5 JP2024533093A5 JP2024513469A JP2024513469A JP2024533093A5 JP 2024533093 A5 JP2024533093 A5 JP 2024533093A5 JP 2024513469 A JP2024513469 A JP 2024513469A JP 2024513469 A JP2024513469 A JP 2024513469A JP 2024533093 A5 JP2024533093 A5 JP 2024533093A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- nkt
- nkp44
- subject
- itcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163239566P | 2021-09-01 | 2021-09-01 | |
| US63/239,566 | 2021-09-01 | ||
| PCT/US2022/042147 WO2023034377A1 (en) | 2021-09-01 | 2022-08-31 | Lymphocyte population and methods for producing same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024533093A JP2024533093A (ja) | 2024-09-12 |
| JP2024533093A5 true JP2024533093A5 (enExample) | 2025-09-08 |
Family
ID=83447808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024513469A Pending JP2024533093A (ja) | 2021-09-01 | 2022-08-31 | リンパ球集団およびその産生方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240358829A1 (enExample) |
| EP (1) | EP4395784A1 (enExample) |
| JP (1) | JP2024533093A (enExample) |
| KR (1) | KR20240055044A (enExample) |
| CN (1) | CN118302171A (enExample) |
| CA (1) | CA3229529A1 (enExample) |
| IL (1) | IL311041A (enExample) |
| WO (1) | WO2023034377A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4017509A4 (en) * | 2019-08-21 | 2023-09-13 | Akeso Therapeutics, Inc. | TYPE III NKT CELLS AND RELATED COMPOSITIONS AND METHODS |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015112793A2 (en) * | 2014-01-27 | 2015-07-30 | St. Jude Children's Research Hospital, Inc. | Methods of expanding ex vivo natural killer t (nkt) cells and therapeutic uses thereof |
| EP3490605B1 (en) | 2017-04-01 | 2023-06-07 | AVM Biotechnology, LLC | Replacement of cytotoxic preconditioning before cellular immunotherapy |
| EP3488851A1 (en) | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
| CA3168378A1 (en) * | 2020-02-28 | 2021-09-02 | Avm Biotechnology, Llc | Lypmphocyte population and methods for producing same |
| KR20230018422A (ko) | 2020-06-01 | 2023-02-07 | 에이브이엠 바이오테크놀로지, 엘엘씨 | Icam-조절제를 이용한 치료 방법 |
-
2022
- 2022-08-31 EP EP22777453.6A patent/EP4395784A1/en active Pending
- 2022-08-31 JP JP2024513469A patent/JP2024533093A/ja active Pending
- 2022-08-31 IL IL311041A patent/IL311041A/en unknown
- 2022-08-31 KR KR1020247010710A patent/KR20240055044A/ko active Pending
- 2022-08-31 WO PCT/US2022/042147 patent/WO2023034377A1/en not_active Ceased
- 2022-08-31 US US18/683,814 patent/US20240358829A1/en active Pending
- 2022-08-31 CN CN202280063410.3A patent/CN118302171A/zh active Pending
- 2022-08-31 CA CA3229529A patent/CA3229529A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Diorio et al. | Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks | |
| KR102883631B1 (ko) | 감마-델타 t 세포 및 자연 살해 세포의 치료 제제 및 제조 및 사용 방법 | |
| Smith et al. | Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin‐4 production and associated eosinophilia | |
| DE102017127984B4 (de) | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen | |
| Vik-Mo et al. | Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma | |
| JP2020518289A5 (enExample) | ||
| CA2413866C (en) | Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations | |
| JP2023123437A (ja) | ガンマデルタｔ細胞およびその使用 | |
| EP1390474B1 (fr) | Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene | |
| McGuckin et al. | Ischemic brain injury: a consortium analysis of key factors involved in mesenchymal stem cell-mediated inflammatory reduction | |
| Čolić et al. | Interleukin‐17 plays a role in exacerbation of inflammation within chronic periapical lesions | |
| Gordon et al. | Adrenal and gonadal steroids inhibit IL-6 secretion by human marrow cells | |
| CN107177548B (zh) | 一种体外扩增淋巴细胞的培养体系及扩增方法和应用 | |
| Meinl et al. | Encephalitogenic potential of myelin basic protein-specific T cells isolated from normal rhesus macaques | |
| WO2011053321A1 (en) | Use of autologous effector cells for treatment of multiple myeloma | |
| JP2024513958A5 (enExample) | ||
| JP2023514788A5 (enExample) | ||
| JP2024513522A5 (enExample) | ||
| JP2024513514A5 (enExample) | ||
| JP2024533093A5 (enExample) | ||
| EP4511056A2 (en) | Allogeneic t cells for treatment of hematological malignancies | |
| JP2022513587A (ja) | 造血幹細胞移植後の回復を実施および促進するための改善 | |
| WO2018013585A1 (en) | Methods and compositions for modulating thymic function | |
| EP0305468A1 (en) | B-cell growth and differentiating factor BCGF 12K for use in therapy | |
| Peng et al. | A cultured malignant B-1 line serves as a model for Richter's syndrome. |